Fig. 4: A combined immunological score comprising sLAG3 concentrations and CD4/CD8 ratio values in peripheral blood is a predictor of progression-free and overall survival in patients undergoing ICI therapy in advanced solid malignancies.

Patients with a baseline CD4/CD8 ratio above the ideal cut-off (1.25) and sLAG3 levels below the ideal-cut off (31.85 pg/ml) (CD4CD8rat^high + sLAG3^low) show a substantially improved progression-free (a) and overall survival (b) compared to patients with an unfavorable CD4CD8rat^low + sLAG3^high profile. During therapy, patients with decreasing CD4/CD8 ratio comparing baseline to the early-time point and sLAG3 levels below a pretreatment ideal cut-off for this subpopulation (sLAG3: 22.64 pg/ml) respond (c) and survive (d) significantly longer than patients with an increasing CD4/CD8 ratio combined with sLAG3 values above the cut-off (increasing CD4/CD8 ratio + sLAG3^high).